摘要
目的:探究协日嘎-4对2型糖尿病大鼠的保护作用及其对血糖血脂调节和肠道菌的影响。方法:通过高糖高脂饲料喂养8周后腹腔注射链脲佐菌素(STZ)建立2型糖尿病模型大鼠。将造模成功的大鼠分为正常对照组、二甲双胍组和剂量协日嘎-4高(5.04 g/kg)、中(2.52 g/kg)、低(1.26 g/kg)剂量组,连续灌胃4周。检测大鼠体质量及空腹血糖(FBG)、三酰甘油(TG)、血清总胆固醇(TC)等生化指标,并通过16SrDNA高通量测序分析肠道菌群变化。结果:协日嘎-4能显著降低2型糖尿病大鼠FBG水平(P<0.05),有效控制体质量减轻(P<0.05),降低TG、TC、HDL水平(P<0.05)。在肠道菌群方面,协日嘎-4可显著升高消化链球菌科、肠乳杆菌等的相对丰度(P<0.05),降低罗斯氏菌(P<0.05);与模型组比较,给药组厚壁菌门(0.806 4±0.106 2)、乳杆菌目(0.421 9±0.265 2)等相对丰度升高,放线菌门(0.143 0±0.067 0)、梭菌纲(0.263 2±0.104 9)等相对丰度降低。结论:协日嘎-4对STZ诱导的2型糖尿病大鼠血糖血脂有调控作用,其作用机制可能与调控肠道菌群失衡相关。
Objective:To investigate the protective effects of Xieriga-4 on rats with type 2 diabetes mellitus(T2DM)and its influence on glucose and lipid metabolism as well as intestinal flora.Methods:A T2DM rat model was established by intraperitoneal injection of streptozotocin(STZ)after 8 weeks of high-sugar and high-fat diet feeding.Successfully modeled rats were divided into a normal control group,a metformin group,and Xieriga-4 high-(5.04 g/kg),medium-(2.52 g/kg),and low-dose(1.26 g/kg)groups,and were administered the corresponding treatments by gavage for 4 consecutive weeks.Body weight and biochemical indices,including fasting blood glucose(FBG),triglycerides(TG),and total cholesterol(TC),were measured.Changes in intestinal flora were analyzed using 16S rDNA high-throughput sequencing.Results:Xieriga-4 significantly reduced FBG levels in T2DM rats(P<0.05),effectively attenuated body weight loss(P<0.05),and decreased TG,TC,and high-density lipoprotein(HDL)levels(P<0.05).Regarding intestinal flora,Xieriga-4 significantly increased the relative abundance of Peptostreptococcaceae and Lactobacillus(P<0.05),while reducing Roseburia(P<0.05).Compared with the model group,the treatment groups showed increased relative abundance of Firmicutes(0.8064±0.1062)and Lactobacillales(0.4219±0.2652),and decreased relative abundance of Actinobacteria(0.1430±0.0670)and Clostridia(0.2632±0.1049).Conclusion:Xieriga-4 exerts regulatory effects on blood glucose and lipid metabolism in STZ-induced T2DM rats,and its mechanism may be associated with the modulation of intestinal flora imbalance.
作者
胡伊力格其
图雅
胡德力根
安其力木格
于淑娟
白小梅
Huyiligeqi;Tuya;Hudeligen;AN Qilimuge;YU Shujuan;BAI Xiaomei(College of Mongolian Medicine and Pharmacy,Inner Mongolia Minzu University,Tongliao 028000 China;Key Laboratory of the Ministry of Education of Mongolian Pharmaceutical Research and Development Engineering,Tongliao 028000 China;Experimental Research Center,China Academy of Chinese Medical Sciences,Beijing 100700,China)
出处
《世界中医药》
北大核心
2025年第18期3253-3259,共7页
World Chinese Medicine
基金
国家自然科学基金面上项目(82274212)
内蒙古自治区自然科学基金项目(2025MS08130)
内蒙古民族大学中药学(蒙药学)重点学科建设项目(ZYX005)
蒙医药研发工程教育部重点实验室开放基金项目(MDK2024025)。
